Cardiac Markers Market By Type (Cardiac Troponin I And T, CK-MB, Myoglobin, B Type Natriuretic Peptide (BNP) And NT-proBNP, hs-C-Reactive Protein (hs-CRP), Myeloperoxidase (MPD), Ischaemia Modified Albumin, Others), By Product (Instruments, Reagents And Kits), By Condition (Plaque Formation, Plaque Instability/ Rupture, Myocardial Necrosis And Ischemia, Heart Failure), By Testing Type (Laboratory Testing, Point-of-Care Testing) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

Cardiac markers are substances released into the bloodstream as a result of heart damage. These markers are detected with specialized immunoassays and are used for the diagnosis, evaluation, and monitoring of patients with suspected acute coronary syndrome. When patients do not have ischemic chest pain and have a non-diagnostic ECG, these markers are extremely useful. The common cardiac markers used for the evaluation of acute coronary syndrome are troponin I and T, CK-MB, and myoglobins. Other biomarkers studied in this report are less specific in nature but are also used for further evaluation in terms of damage to the system. Considering their usefulness, cardiac biomarkers are vital for the diagnosis of acute coronary syndrome, acute myocardial infarction, heart failure, and renal diseases; the prognosis and risk stratification of patients with the coronary syndrome; and for patients that are undergoing pre- and post-reperfusion therapy and interventions.

The key factors driving the growth of the global cardiac markers market are the increasing global prevalence of cardiovascular diseases, rapidly changing lifestyle and dietary patterns, an increasing pool of high-risk geriatric population, and persistent growth in the nature of point-of-care diagnostic solutions. Conversely, the high cost and low specificity of certain tests may hold back the growth of this market. Intensive R&D initiatives and the success of the use of cardiac biomarkers in the detection of congenital coronary diseases are some of the aspects that will open future opportunities in this market.

Market Synopsis

Troponin Tests to Remain the Largest Revenue Segment

Troponin T and I enzymes are normal proteins that are vital for the contractile apparatus of the cardiac myocyte. These enzymes are released into the bloodstream three to four hours after myocardial infarction and can be detected for up to ten days. Troponin has a long half-life, which allows for late diagnosis of myocardial infarction but not of re-infraction. The higher uptake of troponin T and I tests is because these are more sensitive than creatine kinase (CK) and myoglobin. Monoclonal antibody tests are also being developed for the detection of specific troponin T and cardiac troponin I. Cardiac troponins are also used for the diagnosis of chest pain in patients with non-diagnostic ECGs. These tests are also used for the prognosis of myocardial infarction and the identification of patients with a high risk of cardiac events.

Reagents and Kits, as well as Point-of-Care Testing, will continue to be market leaders.

Based on products, the global market for cardiac markers is classified into reagents and kits, and instruments (chemiluminescence, immunofluorescence, immunochromatography, and ELISA). Between the two, the demand for reagents and kits is set to remain the highest during the forecast period. Low costs and greater purchase volume are the key factors considered for the dominance of this segment. However, with technological evolution, the demand for analyzer instruments will remain stable throughout the forecast period. The market growth of the instruments segment is set to remain the highest in emerging markets such as Asia Pacific, Latin America, the Middle East, and Africa, where the rapid development of healthcare infrastructure is being witnessed. At present, point-of-care (POC) immunoassays for several cardiac markers, including troponin I and T, myoglobin, and CK-MB, are available on the market and deliver good quantitative and qualitative results that are comparable to traditional laboratory-based assays. POC cardiac markers are vital in the evaluation of emergency room patients complaining of chest pain. POC assays combining CK-MB and myoglobin have better sensitivity and specificity in the diagnosis of myocardial infarction and may also offer the earliest identification of myocardial injury. Troponin T and Troponin I assays are the most commonly used in POC settings.

myocardial necrosis and ischemia to contribute the highest revenue

Consistent increases in sedentary lifestyle, overall stress levels, changes in dietary habits, smoking, and alcohol use, and a growing geriatric population are the key factors that have resulted in a growing incidence of myocardial infarction. The two well-known biomarkers used for the diagnosis of acute myocardial infarction or necrosis are CK-MB and cardiac troponin. Since 2000, cardiac troponin has successfully replaced CK-MB as the marker of choice for the diagnosis of myocardial infarction. Quick identification of acute myocardial infarction is deemed mandatory for the initiation of effective treatment and a better prognosis. Troponin T is bound to the myocardial contractile cells and presents a dual release of the cytoplasmic component. Troponin I is also extremely specific to the cardiac muscle. Their absolute specificity makes troponin I and T the ideal markers for myocardial necrosis.

Significant market opportunities await Asia Pacific.

Currently, North America leads the global market for cardiac markers. The basic factors supporting North American market dominance are a high incidence of cardiac emergencies, a significantly large proportion of the population leading a sedentary lifestyle, and a high-risk dietary profile. Additionally, the availability of both POC and laboratory-based cardiac marker tests is also widespread in the region, along with high levels of awareness in the general population. However, Asia Pacific is anticipated to progress at the fastest CAGR during the forecast period. Large population pools, along with greater adoption of high-sugar and fat diets, are contributing to the increasing prevalence of chronic heart diseases. This has therefore led to an increase in the adoption of advanced diagnostic tools for the management of such a patient pool. Additionally, as the medical tourism market in the region is flourishing, the demand for advanced diagnostic solutions for cardiac diseases is also on the rise. This has resulted in increased penetration by global market giants to augment their market penetration activities in the Asia Pacific market.

Periods of History and Forecast

This research report presents the analysis of each considered segment for the period from 2016 to 2026, using 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The cardiac markers market report provides a quantitative assessment of the industry in terms of current and forecasted market size while also presenting the market dynamics. This market is segmented based on type, products, conditions, testing type, and geography.

The qualitative analysis presented in this report gives insights into the determinant market dynamics of the cardiac marker industry. Such market dynamics are classified as market drivers, challenges, and opportunities. The major market players involved in the cardiac biomarkers industry are also assessed in terms of their business overview, product portfolio, financial status, and key developments. The prominent market players profiled in this report are Abbott Laboratories, Inc., Roche Diagnostics Limited, Danaher Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, LSI Medience Corporation, Beckman Coulter, Inc. (Danaher Corporation), BioMerieux SA, Ortho Clinical Diagnostics, Siemens Healthcare Diagnostics, Randox Laboratories Ltd., Tosoh Bioscience, and Quest Diagnostics, Inc.

Key questions are answered in this report.

  • What is the estimated market size and CAGR of the global cardiac markers industry during the forecast period from 2018 to 2026?
  • What are the key market drivers and pain points prevalent in the cardiac markers market?
  • In which direction is the CK-MB segment progressing, and will it be challenged by other testing markers?
  • Will the demand for novel analyzer instruments rise during the forecast period?
  • What status do segments such as heart failure and myocardial infarction have in the global market for cardiac markers?
  • At what CAGR will the point-of-care segment progress during the period from 2018 to 2026?
  • How is the global competition progressing among the key market players?
  • Is there a possibility of new market entrants, particularly in the emerging markets of Asia Pacific?

Frequently Asked Questions:

The market for Cardiac Markers Market is expected to reach US$ XX Mn by 2026.

The Cardiac Markers Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Beckman Coulter, Inc. (Danaher Corporation), BioMerieux SA, Ortho Clinical Diagnostics, Siemens Healthcare Diagnostics, Randox Laboratories Ltd., Tosoh Bioscience, and Quest Diagnostics, are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Nov 2018
Category:  Medical Devices
Report ID:   59447
Report Format:   PDF
Pages:   120
Rating:    4.1 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support